Literature DB >> 14337738

PROLONGATION OF SKIN HOMOGRAFT SURVIVAL BY THALIDOMIDE.

K HELLMANN, D I DUKE, D F TUCKER.   

Abstract

Entities:  

Keywords:  EXPERIMENTAL LAB STUDY; IMMUNOSUPPRESSIVE AGENTS; MICE; PHARMACOLOGY; SKIN TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS

Mesh：

Substances：

Year:  1965        PMID： 14337738      PMCID： PMC1846106          DOI： 10.1136/bmj.2.5463.687

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  5 in total

1.  SUPPRESSION OF TISSUE IMMUNITY BY CYCLOPHOSPHAMIDE.

Authors:  M FOX
Journal:  Transplantation       Date:  1964-07       Impact factor: 4.939

2.  THALIDOMIDE AND INDUCED AMPHIBIAN METAMORPHOSIS.

Authors:  J R TATA
Journal:  Nature       Date:  1964-12-05       Impact factor: 49.962

3.  Chemical suppression of the immune response.

Authors:  G H HITCHINGS; G B ELION
Journal:  Pharmacol Rev       Date:  1963-06       Impact factor: 25.468

4.  The use of antigenic tissue extracts to weaken the immunological reaction against skin homografts in mice.

Authors:  P B MEDAWAR
Journal:  Transplantation       Date:  1963-01       Impact factor: 4.939

5.  Alteration of the homograft response by antimetabolites.

Authors:  W R MEEKER; R M CONDIE; R A GOOD; R L VARCO
Journal:  Ann N Y Acad Sci       Date:  1960-05-31       Impact factor: 5.691
  5 in total
  14 in total

1.  Prolonged survival of glutaraldehyde-treated skin homografts.

Authors:  I Schechter
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

2.  [Immunosuppression by cyclic imides in the rat].

Authors:  M Ellenrieder; E Frankus; W Krüpe
Journal:  Klin Wochenschr       Date:  1967-11-15

3.  Effect of ribonucleic acid perfusion on canine kidney and liver homograft survival.

Authors:  C G Groth; K A Porter; P M Daloze; C Huguet; G V Smith; L Brettschneider; T E Starzl
Journal:  Surgery       Date:  1968-07       Impact factor: 3.982

4.  The effect of two soluble thalidomide derivatives on lymphocyte stimulation.

Authors:  A S Coulson; L J Summers; K Lindahl-Kiessling; D Tucker; K Hellmann
Journal:  Clin Exp Immunol       Date:  1970-08       Impact factor: 4.330

5.  Teratogenesis and lymphocyte stimulation.

Authors:  A S Coulson; L J Summers; D R Inman
Journal:  Br Med J       Date:  1969-07-05

Review 6.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

7.  Treatment of Behçet's disease with thalidomide.

Authors:  M H Hamza
Journal:  Clin Rheumatol       Date:  1986-09       Impact factor: 2.980

8.  Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model.

Authors:  Julian W Mall; Wolfgang Schwenk; Andreas W Philipp; Rolf Büttemeyer; Christian Pollmann
Journal:  World J Surg       Date:  2003-09-04       Impact factor: 3.352

9.  Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood.

Authors:  R Neubert; A C Nogueira; D Neubert
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

10.  Immunological alteration of leukemic cells in vivo after treatment with an antitumor drug.

Authors:  E Bonmassar; A Bonmassar; S Vadlamudi; A Goldin
Journal:  Proc Natl Acad Sci U S A       Date:  1970-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.